HRT Financial
ANTX icon

HRT Financial’s AN2 Therapeutics ANTX Stock Holding History

HRT Financial’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32,924
Closed -$112K – 4123
2026
Q1 		$112K Buy
+32,924
New +$67.9K ﹤0.01% 3329
2025
Q3 		– Sell
-12,678
Closed -$13K – 2824
2025
Q2 		$13K Buy
+12,678
New +$15.1K ﹤0.01% 2433
2024
Q2 		– Sell
-24,366
Closed -$79K – 2173
2024
Q1 		$79K Buy
+24,366
New +$265K ﹤0.01% 1883

Other funds holding ANTX

Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Commodore Capital
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Spruce Street Capital
Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return
Almitas Capital
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Boxer Capital Management
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

HRT Financial's ANTX Position: Q2 2026 in Review

HRT Financial sold out of AN2 Therapeutics (ANTX) in Q2 2026, closing a stake of 32,924 shares — an estimated $112K sold.

HRT Financial first reported a position in ANTX in Q1 2024 and held it in 3 quarters. The position peaked at $112K in Q1 2026. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • HRT Financial reported no remaining AN2 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 32,924 AN2 Therapeutics shares in Q2 2026, an estimated $112K.
  • HRT Financial first reported a position in AN2 Therapeutics in Q1 2024 and held it in 3 quarters.
  • HRT Financial's AN2 Therapeutics position peaked at $112K in Q1 2026.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.